HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R21 Basic Experimental Studies with Humans Required) | RFA HD 23 033

Frequently Asked Questions (FAQs): NIH HEAL Initiative RFA-HD-23-033 (R21)

1) What is RFA-HD-23-033?

RFA-HD-23-033 is a funding opportunity under the NIH HEAL (Helping to End Addiction Long-term) Initiative that uses the NIH R21 Exploratory/Developmental Research Grant mechanism. It supports early-stage, high-risk, high-reward studies intended to open new directions in understanding how opioid exposure during pregnancy affects the placenta and infant neurodevelopment.

2) What type of grant mechanism is this, and what is it designed to support?

This opportunity uses the NIH R21 mechanism, which is designed for exploratory or developmental projects that may be conceptual, early-stage, or inherently risky, but that have the potential to generate breakthroughs, produce strong preliminary data, or create new tools, methods, or experimental approaches that could substantially shift the field.

3) What is the main scientific goal of this funding opportunity?

The primary goal is to identify and clarify fundamental biological and behavioral mechanisms linking prenatal opioid exposure to placental function, fetal and infant brain development, and neurodevelopmental outcomes from pregnancy through the first year of life.

4) What exposures are within scope?

The FOA includes opioid exposure alone and opioid exposure combined with other commonly misused substances, reflecting real-world polysubstance exposure patterns.

5) What life stage and outcomes does the FOA emphasize?

The FOA emphasizes pregnancy through the infant's first year of life, focusing on how prenatal opioid-related exposures may influence placental biology and downstream effects on early brain development and measurable neurodevelopmental trajectories in infants.

6) What aspects of placental biology are of interest?

The announcement highlights placental processes such as transport functions, inflammatory signaling, endocrine activity, vascular development, and other placental mechanisms that could be altered by opioid exposure (alone or with other substances) and contribute to later neurodevelopmental outcomes.

7) What makes the required study design different from many other NIH research announcements?

This FOA requires experimental designs in humans that prospectively assign participants to conditions. That means the independent variable is intentionally manipulated, rather than being purely observed in a naturalistic or cohort setting.

8) What does NIH mean by Basic Experimental Studies with Humans (BESH) in this FOA?

NIH classifies these projects as Basic Experimental Studies with Humans (BESH). In practice, that means the research must be basic science in intent (focused on mechanisms and fundamental phenomena) while also meeting the NIH definition of a clinical trial because human participants are assigned to one or more conditions.

9) Are these studies considered clinical trials?

Yes, under NIH definitions they meet the definition of a clinical trial because participants are prospectively assigned to one or more conditions. However, the intent must remain basic science and mechanism-focused rather than clinical efficacy-focused.

10) What types of outcomes can be measured?

Outcomes can be biomedical and/or behavioral. The emphasis is on advancing foundational knowledge about opioid-related processes during pregnancy and infancy, especially those tied to placental function and early neurodevelopment.

11) Is the FOA intended to test treatments or interventions for improved health outcomes?

No. NIH draws a clear boundary that projects should not be aimed at producing clinical outcomes or products as the main objective. Examples of out-of-scope aims include demonstrating improved health outcomes from an intervention, validating a clinical protocol, or developing a deliverable clinical tool as the primary goal.

12) Are purely observational human studies allowed under this FOA?

No. Applications that are purely observational in humans (for example, cohort studies without prospective assignment) are directed to a companion announcement instead.

13) Are animal model studies allowed under this FOA?

No. Applications that include model animal research are directed to the companion announcement rather than this one.

14) What is the companion announcement mentioned, and when should applicants consider it?

The companion announcement is RFA-HD-23-031. It is described as the R21 pathway where clinical trials are not allowed, and it is the appropriate route for applications that are observational in humans or that include animal model research.

15) How should applicants decide whether to apply to RFA-HD-23-033 versus the companion FOA?

Applicants should match the FOA to the study design. RFA-HD-23-033 is for experimentally manipulated, prospectively assigned human studies that are basic science in purpose (BESH). Observational human studies and/or animal model research should be directed to RFA-HD-23-031.

16) Who is eligible to apply?

Eligibility is broad and includes many standard applicant types, such as state, county, city, township, and special district governments; independent school districts; public and state-controlled and private institutions of higher education; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; Native American tribal organizations other than federally recognized governments; nonprofit organizations with and without 501(c)(3) status; for-profit organizations (other than small businesses) and small businesses; and other eligible entities.

17) Are specific institution types highlighted as eligible?

Yes. NIH highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities, faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.

18) Are foreign institutions eligible to apply as the main applicant?

No. Foreign institutions (non-U.S. entities) are not eligible to apply.

19) Can a U.S. applicant include non-U.S. components in the project?

Non-U.S. components of U.S. organizations are not eligible. However, foreign components (as defined under the NIH Grants Policy Statement) may be allowed, which generally means a U.S. applicant can include certain justified international elements under NIH rules.

20) Which federal agency administers this opportunity?

This is a discretionary grant opportunity administered by the National Institutes of Health (NIH) under the HEAL Initiative.

21) What are the CFDA numbers associated with this opportunity?

The opportunity listing is associated with multiple CFDA numbers: 93.242, 93.273, 93.279, 93.853, and 93.865.

22) When was this opportunity created, and what closing date is listed?

The opportunity was created on 2022-08-29. The original closing date listed in the provided information is 2022-12-07.

23) Is there an award ceiling or a stated number of expected awards?

Not in the provided listing. The award ceiling and expected number of awards are not specified, which can occur for some NIH announcements where budgets and award counts depend on appropriations, program priorities, and application quality.

24) What is the overall "fit" for a strong application under this FOA?

A strong fit is a creative, mechanism-driven human experimental study that prospectively assigns participants to conditions, focuses on fundamental biological and/or behavioral mechanisms linking prenatal opioid-related exposures to placental function and early neurodevelopment, and generates foundational insights that can later inform clinical and public health approaches without making clinical efficacy the central endpoint.